Concepedia

Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2

Anne Vest Soerensen, Frede Donskov, Jakob Kjellberg, Rikke Ibsen, Gregers G. Hermann, Niels Viggo Jensen, Kirsten Fode, Poul Geertsen

European Urology · 2014 · 14 citations · 28 references

DOIFull text

Open access

Abstract

In this nationwide study, we found changes in the pattern of health care costs for patients with metastatic kidney cancer after implementation of targeted therapy compared to an immunotherapy control period; however, total health care costs and income from employment were without significant changes.

References

28

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.3K citations

, , +16

Cancer statistics, 2014

Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.5K citations · Full text

, , +17

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.7K citations · Full text

The Danish National Patient Register

Elsebeth Lynge, Jakob Lynge Sandegaard, Matejka Rebolj · Scandinavian Journal of Public Health · 2011 · 3.9K citations

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bernard Escudier, P. Koralewski, Alain Ravaud et al. · The Lancet · 2007 · 2.2K citations

, , +4